PharmAbcine, Inc.

This year’s BIO International Convention in the US saw the strongest ever participation from South Korea, with 544 companies from the relatively small country reportedly registered and the number of K

Amid the ongoing global financial strains and a high interest rate environment, bioventures in South Korea are increasingly opting to raise funds through rights offerings, despite concerns over share

As Korean biopharma firms, particularly bioventures, are suffering from a sharp decline in financing and licensing deals, the role of the state-supported Korea Drug Development Fund (KDDF) is becoming

Australia is becoming a clinical trial hot spot for South Korean biotech and pharma firms, with companies such as PharmAbcine, Inc. , KoBioLabs, Inc. and Daewoong Pharmaceutical Company Ltd. incr